Frank Tacke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/577222/publications.pdf

Version: 2024-02-01

580 papers 50,031 citations

105 h-index 201

617 all docs

617 docs citations

617 times ranked

51834 citing authors

g-index

#	Article	IF	Citations
1	Distribution of gastrointestinal neuroendocrine tumors in Europe: results from a retrospective cross-sectional study. Journal of Cancer Research and Clinical Oncology, 2023, 149, 1411-1416.	2.5	3
2	Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling. Seminars in Cancer Biology, 2022, 84, 129-143.	9.6	41
3	Next-Generation Imaging: New Insights from Multicolor Microscopy in Liver Biology and Disease. Engineering, 2022, 9, 17-21.	6.7	1
4	An elevated FIB-4 score predicts liver cancer development: A longitudinal analysis from 29,999 patients with NAFLD. Journal of Hepatology, 2022, 76, 247-248.	3.7	25
5	Shear wave elastography and shear wave dispersion imaging in primary biliary cholangitis—a pilot study. Quantitative Imaging in Medicine and Surgery, 2022, 12, 1235-1242.	2.0	10
6	Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 60-78.	17.8	330
7	Genetic Variant of CXCR1 (rs2234671) Associates with Clinical Outcome in Perihilar Cholangiocarcinoma. Liver Cancer, 2022, 11, 162-173.	7.7	9
8	Evaluation of Inhibitory Antibodies against the Muscarinic Acetylcholine Receptor Type 3 in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Journal of Clinical Medicine, 2022, 11, 681.	2.4	0
9	The Potential Role of Cellular Senescence in Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2022, 23, 652.	4.1	27
10	The fecal mycobiome in non-alcoholic fatty liver disease. Journal of Hepatology, 2022, 76, 788-799.	3.7	66
11	A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. Alimentary Pharmacology and Therapeutics, 2022, 55, 234-243.	3.7	11
12	Single Cell RNA Sequencing in NASH. Methods in Molecular Biology, 2022, 2455, 181-202.	0.9	9
13	Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2022, 23, 2668.	4.1	42
14	Prognostic and Predictive Molecular Markers in Cholangiocarcinoma. Cancers, 2022, 14, 1026.	3.7	17
15	Ferroptosis in Cancer Immunotherapyâ€"Implications for Hepatocellular Carcinoma. Immuno, 2022, 2, 185-217.	1.5	3
16	Many roads lead to Rome: The FGF4–AMPâ€activated protein kinase–Caspase 6 signal axis in NAFLD and NASH. Hepatology, 2022, 76, 911-913.	7.3	2
17	The arginine methyltransferase PRMT7 promotes extravasation of monocytes resulting in tissue injury in COPD. Nature Communications, 2022, 13, 1303.	12.8	42
18	Location, location, location — spatial insight into hepatic macrophage populations. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 281-282.	17.8	5

#	Article	IF	CITATIONS
19	Studying metabolism with multi-organ chips: new tools for disease modelling, pharmacokinetics and pharmacodynamics. Open Biology, 2022, 12, 210333.	3.6	12
20	Effects of COPD on Left Ventricular and Left Atrial Deformation in Patients with Acute Myocardial Infarction: Strain Analysis Using Speckle-Tracking Echocardiography. Journal of Clinical Medicine, 2022, 11, 1917.	2.4	1
21	Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic) Tj ETQq1 1 0.784	31 4 9gBT	/Overlock 10
22	Portal fibroblasts with mesenchymal stem cell features form a reservoir of proliferative myofibroblasts in liver fibrosis. Hepatology, 2022, 76, 1360-1375.	7.3	30
23	BMP feed-forward loop promotes terminal differentiation in gastric glands and is interrupted by H. pylori-driven inflammation. Nature Communications, 2022, 13, 1577.	12.8	19
24	Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany. Journal of Viral Hepatitis, 2022, 29, 536-542.	2.0	14
25	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. Journal of Hepatology, 2022, 76, 771-780.	3.7	114
26	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. The Lancet Gastroenterology and Hepatology, 2022, 7, 396-415.	8.1	237
27	Macrophages in cholangiopathies. Current Opinion in Gastroenterology, 2022, 38, 114-120.	2.3	7
28	Low Serum Levels of Soluble Receptor Activator of Nuclear Factor \hat{l}^2 B Ligand (sRANKL) Are Associated with Metabolic Dysregulation and Predict Long-Term Mortality in Critically III Patients. Diagnostics, 2022, 12, 62.	2.6	1
29	Novel drug discovery strategies for the treatment of decompensated cirrhosis. Expert Opinion on Drug Discovery, 2022, 17, 273-282.	5.0	0
30	Immature neutrophils bring anti-PD-1 therapy in NASH-HCC to maturity. Gut, 2022, 71, 1937-1938.	12.1	1
31	Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis. Journal of Clinical Medicine, 2022, 11, 2479.	2.4	2
32	The macrophage-associated microRNA-4715-3p $\!\!\!/$ Gasdermin D axis potentially indicates fibrosis progression in nonalcoholic fatty liver disease: evidence from transcriptome and biological data. Bioengineered, 2022, 13, 11740-11751.	3.2	2
33	Mathematical Arterialization of Capillary Blood for Blood Gas Analysis in Critically Ill Patients. Respiration, 2022, 101, 738-745.	2.6	1
34	The prognostic impact of preoperative body composition in perihilar and intrahepatic cholangiocarcinoma. Hepatology Communications, 2022, 6, 2400-2417.	4. 3	6
35	Outcome of liver cancer patients with SARSâ€CoVâ€2 infection: An International, Multicentre, Cohort Study. Liver International, 2022, 42, 1891-1901.	3.9	11
36	Review article: vascular effects of <scp>PPARs</scp> in the context of <scp>NASH</scp> . Alimentary Pharmacology and Therapeutics, 2022, 56, 209-223.	3.7	9

#	Article	IF	CITATIONS
37	Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis Câ€Registry. Hepatology Communications, 2022, 6, 2488-2495.	4.3	6
38	Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD). International Journal of Molecular Sciences, 2022, 23, 6996.	4.1	8
39	Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis. International Journal of Molecular Sciences, 2022, 23, 6696.	4.1	24
40	Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19. PLoS Pathogens, 2022, 18, e1010547.	4.7	12
41	Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease – novel insights into cellular communication circuits. Journal of Hepatology, 2022, 77, 1136-1160.	3.7	136
42	Understanding the cellular interactome of non-alcoholic fatty liver disease. JHEP Reports, 2022, 4, 100524.	4.9	35
43	Gastric stem cells promote inflammation and gland remodeling in response to <i>Helicobacter pylori</i> via <scp>Rspo3‣gr4</scp> axis. EMBO Journal, 2022, 41, .	7.8	13
44	The Role of Immunosuppression for Recurrent Cholangiocellular Carcinoma after Liver Transplantation. Cancers, 2022, 14, 2890.	3.7	2
45	Distinct histopathological phenotypes of severe alcoholic hepatitis suggest different mechanisms driving liver injury and failure. Journal of Clinical Investigation, 2022, 132, .	8.2	23
46	Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions. Neuroendocrinology, 2021, 111, 217-236.	2.5	17
47	De Novo Development of Distal Jejunal and Duodenal Adenomas After 41 Months of Teduglutide Treatment in a Patient With Shortâ€Bowel Syndrome: A Case Report. Journal of Parenteral and Enteral Nutrition, 2021, 45, 652-656.	2.6	11
48	Roles of CCR2 and CCR5 for Hepatic Macrophage Polarization in Mice With Liver Parenchymal Cell-Specific NEMO Deletion. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 327-347.	4.5	23
49	Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 24-39.	17.8	174
50	Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. Cellular and Molecular Immunology, 2021, 18, 45-56.	10.5	294
51	Evaluation of Fontan failure by classifying the severity of Fontan-associated liver disease: a single-centre cross-sectional study. European Journal of Cardio-thoracic Surgery, 2021, 59, 341-348.	1.4	9
52	Gadoxetic acid-enhanced MRI in primary sclerosing cholangitis: added value in assessing liver function and monitoring disease progression. Abdominal Radiology, 2021, 46, 979-991.	2.1	5
53	Impact of spontaneous splenorenal shunt on liver volume and longâ€term survival of liver cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1694-1702.	2.8	21
54	MAdCAM- $1/\hat{l}\pm4\hat{l}^27$ Integrin-Mediated Lymphocyte/Endothelium Interactions Exacerbate Acute Immune-Mediated Hepatitis in Mice. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 1227-1250.e1.	4.5	8

#	Article	IF	CITATIONS
55	Intestinal microbiota drives cholestasis-induced specific hepatic gene expression patterns. Gut Microbes, 2021, 13, 1-20.	9.8	16
56	Early risk markers for severe clinical course and fatal outcome in German patients with COVID-19. PLoS ONE, 2021, 16, e0246182.	2.5	7
57	Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma. Cancers, 2021, 13, 730.	3.7	35
58	The role of recipient myosteatosis in graft and patient survival after deceased donor liver transplantation. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 358-367.	7.3	28
59	Elevated soluble urokinase plasminogen activator receptor serum levels indicate poor survival following transarterial chemoembolization therapy for hepatic malignancies: An exploratory analysis. JGH Open, 2021, 5, 356-363.	1.6	O
60	From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis. International Journal of Molecular Sciences, 2021, 22, 1492.	4.1	16
61	Therapeutic depletion of CCR8 ⁺ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy., 2021, 9, e001749.		91
62	Serum levels of circulating microRNA-107 are elevated in patients with early-stage HCC. PLoS ONE, 2021, 16, e0247917.	2.5	9
63	Epithelial response to IFNâ€Ĵ³ promotes SARSâ€CoVâ€2 infection. EMBO Molecular Medicine, 2021, 13, e13191.	6.9	62
64	JNK signaling prevents biliary cyst formation through a CASPASE-8–dependent function of RIPK1 during aging. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	8
65	Real-World Clinical Management of Patients with Primary Biliary Cholangitisâ€"A Retrospective Multicenter Study from Germany. Journal of Clinical Medicine, 2021, 10, 1061.	2.4	11
66	Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH. Nature, 2021, 592, 444-449.	27.8	233
67	Recurrence of Hepatocellular Carcinoma After Liver Transplantation is Associated with Episodes of Acute Rejections. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 133-143.	3.7	10
68	Progressive Sarcopenia Correlates with Poor Response and Outcome to Immune Checkpoint Inhibitor Therapy. Journal of Clinical Medicine, 2021, 10, 1361.	2.4	16
69	Shear Wave Elastography and Shear Wave Dispersion Imaging in the Assessment of Liver Disease in Alpha1-Antitrypsin Deficiency. Diagnostics, 2021, 11, 629.	2.6	4
70	Minimization of Immunosuppressive Therapy Is Associated with Improved Survival of Liver Transplant Patients with Recurrent Hepatocellular Carcinoma. Cancers, 2021, 13, 1617.	3.7	11
71	Monocyte dysregulation: consequences for hepatic infections. Seminars in Immunopathology, 2021, 43, 493-506.	6.1	4
72	CT-based determination of excessive visceral adipose tissue is associated with an impaired survival in critically ill patients. PLoS ONE, 2021, 16, e0250321.	2.5	6

#	Article	IF	Citations
73	European †NAFLD Preparedness Index††Is Europe ready to meet the challenge of fatty liver disease?. JHEP Reports, 2021, 3, 100234.	4.9	27
74	Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy. Frontiers in Oncology, 2021, 11, 646883.	2.8	7
75	Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. Annals of Translational Medicine, 2021, 9, 729-729.	1.7	71
76	Shear Wave Elastography in the Detection of Sinusoidal Obstruction Syndrome in Adult Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation. Diagnostics, 2021, 11, 928.	2.6	6
77	Bile acid–activated macrophages promote biliary epithelial cell proliferation through integrin αvβ6 upregulation following liver injury. Journal of Clinical Investigation, 2021, 131, .	8.2	46
78	A radiomics-based model to classify the etiology of liver cirrhosis using gadoxetic acid-enhanced MRI. Scientific Reports, 2021, 11, 10778.	3.3	10
79	Combined analysis of gut microbiota, diet and <i>PNPLA3</i> polymorphism in biopsyâ€proven nonâ€alcoholic fatty liver disease. Liver International, 2021, 41, 1576-1591.	3.9	11
80	CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function. Immunology, 2021, 163, 512-520.	4.4	46
81	The therapeutic landscape of hepatocellular carcinoma. Med, 2021, 2, 505-552.	4.4	20
82	Six Months Follow-Up of Patients with Invasive Mechanical Ventilation Due to COVID-19 Related ARDS. International Journal of Environmental Research and Public Health, 2021, 18, 5861.	2.6	20
83	Pharmacotherapy Profiles in People with Opioid Use Disorders: Considerations for Relevant Drug–Drug Interactions with Antiviral Treatments for Hepatitis C. Pathogens, 2021, 10, 648.	2.8	1
84	In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 650486.	4.8	26
85	Serum levels of soluble B and T lymphocyte attenuator predict overall survival in patients undergoing immune checkpoint inhibitor therapy for solid malignancies. International Journal of Cancer, 2021, 149, 1189-1198.	5.1	17
86	Clinical utility of quantifying hepatitis B surface antigen in African patients with chronic hepatitis B. Journal of Viral Hepatitis, 2021, 28, 1003-1010.	2.0	2
87	Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP Reports, 2021, 3, 100260.	4.9	36
88	The Role of Microbiota in Primary Sclerosing Cholangitis and Related Biliary Malignancies. International Journal of Molecular Sciences, 2021, 22, 6975.	4.1	22
89	Levels of Circulating PD-L1 Are Decreased in Patients with Resectable Cholangiocarcinoma. International Journal of Molecular Sciences, 2021, 22, 6569.	4.1	3
90	An Unexpected Line of Defense: Hepatoprotective Eosinophils in Ischemiaâ∈Reperfusion Injury. Hepatology, 2021, 74, 2888-2890.	7.3	1

#	Article	IF	CITATIONS
91	Donor-Specific Antibodies Against Donor Human Leukocyte Antigen are Associated with Graft Inflammation but Not with Fibrosis Long-Term After Liver Transplantation: An Analysis of Protocol Biopsies. Journal of Inflammation Research, 2021, Volume 14, 2697-2712.	3.5	5
92	Editorial: Overcoming the Immune Microenvironment of Hepatocellular Cancer. Frontiers in Immunology, 2021, 12, 707329.	4.8	1
93	Bronchoâ€alveolar lavage in patients with acute respiratory distress syndrome due to COVIDâ€19. Internal Medicine Journal, 2021, 51, 965-967.	0.8	3
94	Neuropsychobiological Fingerprints of Chronic Fatigue in Sarcoidosis. Frontiers in Behavioral Neuroscience, 2021, 15, 633005.	2.0	3
95	Mobile 3-dimensional (3D) C-arm system-assisted transbronchial biopsy and ablation for ground-glass opacity pulmonary nodules: a case report. Translational Lung Cancer Research, 2021, 10, 3312-3319.	2.8	10
96	Hypothermic Oxygenated Machine Perfusion Reduces Early Allograft Injury and Improves Post-transplant Outcomes in Extended Criteria Donation Liver Transplantation From Donation After Brain Death. Annals of Surgery, 2021, 274, 705-712.	4.2	118
97	Liver Injury and the Macrophage Issue: Molecular and Mechanistic Facts and Their Clinical Relevance. International Journal of Molecular Sciences, 2021, 22, 7249.	4.1	30
98	The APAC Score: A Novel and Highly Performant Serological Tool for Early Diagnosis of Hepatocellular Carcinoma in Patients with Liver Cirrhosis. Journal of Clinical Medicine, 2021, 10, 3392.	2.4	14
99	Predicting survival after TIPS: Child Pugh score is not inferior to MELD and FIPS score – back to basics?. Journal of Hepatology, 2021, 75, 1505-1506.	3.7	2
100	Effects of Transcatheter Mitral Valve Repair Using MitraClip \hat{A}^{\otimes} Device on Sleep Disordered Breathing in Patients with Mitral Valve Regurgitation. Journal of Clinical Medicine, 2021, 10, 3332.	2.4	3
101	Circulating Osteopontin Levels and Outcomes in Patients Hospitalized for COVID-19. Journal of Clinical Medicine, 2021, 10, 3907.	2.4	17
102	The Role of miRNA in the Pathophysiology of Neuroendocrine Tumors. International Journal of Molecular Sciences, 2021, 22, 8569.	4.1	8
103	Decreased Bone Mineral Density Is a Predictor of Poor Survival in Critically III Patients. Journal of Clinical Medicine, 2021, 10, 3741.	2.4	3
104	Telomere Shortening in Peripheral Leukocytes Is Associated With Poor Survival in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy. Frontiers in Oncology, 2021, 11, 729207.	2.8	5
105	Alexithymia and Facial Mimicry in Response to Infant and Adult Affect-Expressive Faces. Frontiers in Psychology, 2021, 12, 635648.	2.1	1
106	Cardiac Magnetic Resonance Reveals Incipient Cardiomyopathy Traits in Adult Patients With Phenylketonuria. Journal of the American Heart Association, 2021, 10, e020351.	3.7	4
107	Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases. Frontiers in Medicine, 2021, 8, 725390.	2.6	30
108	Safety of transanal ileal pouch-anal anastomosis for ulcerative colitis: a retrospective observational cohort study. Patient Safety in Surgery, 2021, 15, 31.	2.3	6

#	Article	IF	CITATIONS
109	Serum Perilipin 2 (PLIN2) Predicts Multiple Organ Dysfunction in Critically Ill Patients. Biomedicines, 2021, 9, 1210.	3.2	3
110	Elevated Flt3L Predicts Long-Term Survival in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. Cancers, 2021, 13, 4463.	3.7	2
111	Bile Acids Activate NLRP3 Inflammasome, Promoting Murine Liver Inflammation or Fibrosis in a Cell Type-Specific Manner. Cells, 2021, 10, 2618.	4.1	17
112	Evolution of Nonmalignant Portal Vein Thrombosis in Liver Cirrhosis: A Pictorial Review. Clinical and Translational Gastroenterology, 2021, 12, e00409.	2.5	8
113	Clinical course of COVID-19 patients needing supplemental oxygen outside the intensive care unit. Scientific Reports, 2021, 11, 2256.	3.3	35
114	PD-L1 – inhibitors in neuroendocrine neoplasia. Medicine (United States), 2021, 100, e23835.	1.0	7
115	Circulating Bile Acids in Liver Failure Activate TGR5 and Induce Monocyte Dysfunction. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 25-40.	4.5	29
116	When Is a Critically III Cirrhotic Patient Too Sick to Transplant? Development of Consensus Criteria by a Multidisciplinary Panel of 35 International Experts. Transplantation, 2021, 105, 561-568.	1.0	39
117	Prolonged Survival of a Patient with Advanced-Stage Combined Hepatocellular-Cholangiocarcinoma. Case Reports in Gastroenterology, 2021, 14, 658-667.	0.6	6
118	Haemorrhagic ulcerative duodenitis in a patient with COVID-19 infection: clinical improvement following treatment with budesonide. BMJ Open Gastroenterology, 2021, 8, e000757.	2.7	4
119	CCR6 Deficiency Increases Infarct Size after Murine Acute Myocardial Infarction. Biomedicines, 2021, 9, 1532.	3.2	1
120	Comparative Analysis of Circulating Biomarkers for Patients Undergoing Resection of Colorectal Liver Metastases. Diagnostics, 2021, 11, 1999.	2.6	3
121	Cyclin E1 in Murine and Human Liver Cancer: A Promising Target for Therapeutic Intervention during Tumour Progression. Cancers, 2021, 13, 5680.	3.7	5
122	It is in your faceâ€"Alexithymia impairs facial mimicry Emotion, 2021, 21, 1537-1549.	1.8	5
123	Successful treatment of prolonged COVID-19 with Bamlanivimab in a patient with severe B-Cell aplasia due to treatment with an anti-CD20 monoclonal antibody: A case report. Respiratory Medicine Case Reports, 2021, 34, 101560.	0.4	7
124	Liver Fibrosisâ€"From Mechanisms of Injury to Modulation of Disease. Frontiers in Medicine, 2021, 8, 814496.	2.6	9
125	Creation and validation of the Picture-Set of Young Children's Affective Facial Expressions (PSYCAFE). PLoS ONE, 2021, 16, e0260871.	2.5	1
126	Morphologic Alterations Precede Functional Hepatic Impairment as Determined by 13C-Methacetin Liver Function Breath Test in Adult Fontan Patients. Frontiers in Cardiovascular Medicine, 2021, 8, 764009.	2.4	1

#	Article	IF	Citations
127	Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis. Gut, 2020, 69, 551-563.	12.1	142
128	Hepatic Fibrogenesis., 2020,, 89-95.		0
129	A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. Journal of Hepatology, 2020, 72, 14-24.	3.7	123
130	Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs. Liver International, 2020, 40, 539-548.	3.9	24
131	The Unexpected Role of Neutrophils for Resolving Liver Inflammation by Transmitting MicroRNAâ€223 to Macrophages. Hepatology, 2020, 71, 749-751.	7.3	16
132	Differential Gene Expression in Circulating CD14+ Monocytes Indicates the Prognosis of Critically Ill Patients with Sepsis. Journal of Clinical Medicine, 2020, 9, 127.	2.4	18
133	Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. Contemporary Clinical Trials, 2020, 89, 105922.	1.8	92
134	From the Editor's Desk…. Journal of Hepatology, 2020, 72, 1-4.	3.7	1
135	Risk of Stroke in Liver Cirrhosis. Journal of Clinical Gastroenterology, 2020, 54, 96-105.	2.2	17
136	Evaluation of muscarinic acetylcholine receptor typeÂ3 gene polymorphisms in patients with primary biliary cholangitis and primary sclerosing cholangitis. Hepatology Research, 2020, 50, 321-329.	3.4	4
137	New drugs for NAFLD: lessons from basic models to the clinic. Hepatology International, 2020, 14, 8-23.	4.2	61
138	Left- versus right-sided hepatectomy with hilar en-bloc resection in perihilar cholangiocarcinoma. Hpb, 2020, 22, 437-444.	0.3	33
139	Soluble Urokinase Receptor (SuPAR) in COVID-19–Related AKI. Journal of the American Society of Nephrology: JASN, 2020, 31, 2725-2735.	6.1	93
140	Clinical relevance of plasma virome dynamics in liver transplant recipients. EBioMedicine, 2020, 60, 103009.	6.1	21
141	Follow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae. Respiratory Medicine, 2020, 174, 106197.	2.9	235
142	Dendritic Cell and T Cell Crosstalk in Liver Fibrogenesis and Hepatocarcinogenesis: Implications for Prevention and Therapy of Liver Cancer. International Journal of Molecular Sciences, 2020, 21, 7378.	4.1	62
143	In Vivo Models for Cholangiocarcinoma—What Can We Learn for Human Disease?. International Journal of Molecular Sciences, 2020, 21, 4993.	4.1	8
144	Outcomes of Liver Resections after Liver Transplantation at a High-Volume Hepatobiliary Center. Journal of Clinical Medicine, 2020, 9, 3685.	2.4	3

#	Article	IF	Citations
145	Association of Serum Calprotectin Concentrations with Mortality in Critically III and Septic Patients. Diagnostics, 2020, 10, 990.	2.6	14
146	Current Challenges in the Post-Transplant Care of Liver Transplant Recipients in Germany. Journal of Clinical Medicine, 2020, 9, 3570.	2.4	12
147	Prevention and Management of CMV Infections after Liver Transplantation: Current Practice in German Transplant Centers. Journal of Clinical Medicine, 2020, 9, 2352.	2.4	9
148	Dexamethasone nanomedicines for COVID-19. Nature Nanotechnology, 2020, 15, 622-624.	31.5	138
149	Acetyl-CoA Carboxylase Inhibition as a Therapeutic Tool in the Battle Against NASH: Hitting More Than Just One Mechanism?. Cellular and Molecular Gastroenterology and Hepatology, 2020, 10, 859-861.	4.5	3
150	Responses of gastric epithelial stem cells and their niche to Helicobacter pylori infection. Annals of Translational Medicine, 2020, 8, 568-568.	1.7	8
151	Deciphering the Immune Microenvironment on A Single Archival Formalin-Fixed Paraffin-Embedded Tissue Section by An Immediately Implementable Multiplex Fluorescence Immunostaining Protocol. Cancers, 2020, 12, 2449.	3.7	22
152	Midregional Proadrenomedullin (MRproADM) Serum Levels in Critically Ill Patients Are Associated with Short-Term and Overall Mortality during a Two-Year Follow-Up. Mediators of Inflammation, 2020, 2020, 1-10.	3.0	5
153	Circulating levels of microRNA193a-5p predict outcome in early stage hepatocellular carcinoma. PLoS ONE, 2020, 15, e0239386.	2.5	11
154	Low Myostatin Serum Levels Are Associated with Poor Outcome in Critically Ill Patients. Diagnostics, 2020, 10, 574.	2.6	9
155	The socioeconomic aspects of nonalcoholic fatty liver disease: food insecurity as a novel risk factor for steatosis and liver fibrosis. Hepatobiliary Surgery and Nutrition, 2020, 9, 543-545.	1.5	8
156	Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumorsâ€"Results from an Exploratory Study. Journal of Clinical Medicine, 2020, 9, 2881.	2.4	8
157	Skeletal Muscle Composition Predicts Outcome in Critically Ill Patients. , 2020, 2, e0171.		34
158	<p>Identifying High-Risk NASH Patients: What We Know so Far</p> . Hepatic Medicine: Evidence and Research, 2020, Volume 12, 125-138.	2.5	18
159	Ecto-Nucleotide Triphosphate Diphosphohydrolase-2 (NTPDase2) Deletion Increases Acetaminophen-Induced Hepatotoxicity. International Journal of Molecular Sciences, 2020, 21, 5998.	4.1	4
160	Treatment of Anti-HLA Donor-Specific Antibodies Results in Increased Infectious Complications and Impairs Survival after Liver Transplantation. Journal of Clinical Medicine, 2020, 9, 3986.	2.4	2
161	Use of Web-Based Videos in a Community Pharmacy to Optimize Inhalation Technique.International Journal of COPD, 2020, Volume 15, 3367-3373.	2.3	5
162	Impact of Angiogenesis- and Hypoxia-Associated Polymorphisms on Tumor Recurrence in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection. Cancers, 2020, 12, 3826.	3.7	11

#	Article	IF	Citations
163	Inhibition of LTÎ ² R signalling activates WNT-induced regeneration in lung. Nature, 2020, 588, 151-156.	27.8	81
164	Assessing Non-Invasive Liver Function in Patients with Intestinal Failure Receiving Total Parenteral Nutritionâ€"Results from the Prospective PNLiver Trial. Nutrients, 2020, 12, 1217.	4.1	8
165	Resistanceâ€associated substitutions in patients with chronic hepatitis C virus genotype 4 infection. Journal of Viral Hepatitis, 2020, 27, 974-986.	2.0	12
166	Enhancing the Efficacy of CAR T Cells in the Tumor Microenvironment of Pancreatic Cancer. Cancers, 2020, 12, 1389.	3.7	25
167	How effective are nonalcoholic fatty liver disease models for drug discovery?. Expert Opinion on Drug Discovery, 2020, 15, 1237-1240.	5.0	8
168	Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19). Infection, 2020, 48, 619-626.	4.7	79
169	Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis. Expert Opinion on Pharmacotherapy, 2020, 21, 1637-1649.	1.8	42
170	The NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis. Seminars in Liver Disease, 2020, 40, 298-306.	3.6	63
171	Recent Advances and the Potential for Clinical Use of Autofluorescence Detection of Extra-Ophthalmic Tissues. Molecules, 2020, 25, 2095.	3.8	13
172	Recent Advances in Practical Methods for Liver Cell Biology: A Short Overview. International Journal of Molecular Sciences, 2020, 21, 2027.	4.1	10
173	Favorable COVIDâ€19 course despite significant comorbidities in a ruxolitinibâ€treated patient with primary myelofibrosis. European Journal of Haematology, 2020, 105, 655-658.	2.2	24
174	The Effects of MELD-Based Liver Allocation on Patient Survival and Waiting List Mortality in a Country with a Low Donation Rate. Journal of Clinical Medicine, 2020, 9, 1929.	2.4	8
175	Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E – The HepNet SofE pilot study. Journal of Hepatology, 2020, 73, 696-699.	3.7	39
176	Eosinophils and Purinergic Signaling in Health and Disease. Frontiers in Immunology, 2020, 11, 1339.	4.8	11
177	Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease. Gastroenterology, 2020, 159, 1839-1852.	1.3	103
178	Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistanceâ€associated substitutions. Liver International, 2020, 40, 2660-2671.	3.9	2
179	A case report of an excellent response to interferon- α in a patient with functional metastasized neuroendocrine tumor refractory to other treatments. Medicine (United States), 2020, 99, e20820.	1.0	1
180	Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies. Journal of Clinical Medicine, 2020, 9, 1647.	2.4	6

#	Article	IF	CITATIONS
181	Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies. Hepatic Oncology, 2020, 7, HEP20.	4.2	30
182	The role of the innate immune system in the development and treatment of hepatocellular carcinoma. Hepatic Oncology, 2020, 7, HEP17.	4.2	46
183	Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer. JHEP Reports, 2020, 2, 100080.	4.9	17
184	Current status of immunotherapy in gastrointestinal malignancies. Zeitschrift Fur Gastroenterologie, 2020, 58, 542-555.	0.5	5
185	Elevated circulating CD14++CD16+ intermediate monocytes are independently associated with extracardiac complications after cardiac surgery. Scientific Reports, 2020, 10, 947.	3.3	17
186	Regeneration in acute-on-chronic liver failure – the phantom lost its camouflage. Journal of Hepatology, 2020, 72, 610-612.	3.7	10
187	Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. Hepatology, 2020, 72, 892-905.	7.3	227
188	Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges. Expert Opinion on Investigational Drugs, 2020, 29, 89-92.	4.1	27
189	Risk Prediction for Acute Kidney Injury — Super Important, Now suPAR Easy?. New England Journal of Medicine, 2020, 382, 470-472.	27.0	3
190	Rituximab-Containing Treatment Regimens May Imply a Long-Term Risk for Difficult-To-Treat Chronic Hepatitis E. International Journal of Environmental Research and Public Health, 2020, 17, 341.	2.6	7
191	Severity of Fontan-Associated Liver Disease Correlates with Fontan Hemodynamics. Pediatric Cardiology, 2020, 41, 736-746.	1.3	37
192	Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophagesâ †. Journal of Hepatology, 2020, 73, 757-770.	3.7	154
193	Ischemia-Reperfusion Injury in Marginal Liver Grafts and the Role of Hypothermic Machine Perfusion: Molecular Mechanisms and Clinical Implications. Journal of Clinical Medicine, 2020, 9, 846.	2.4	71
194	The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis. Journal of Clinical Medicine, 2020, 9, 1140.	2.4	49
195	Serum levels of bone sialoprotein correlate with portal pressure in patients with liver cirrhosis. PLoS ONE, 2020, 15, e0231701.	2.5	4
196	High Protein Intake Is Associated With Histological Disease Activity in Patients With NAFLD. Hepatology Communications, 2020, 4, 681-695.	4.3	28
197	Solid organ transplantation programs facing lack of empiric evidence in the COVID-19 pandemic: A By-proxy Society Recommendation Consensus approach. American Journal of Transplantation, 2020, 20, 1826-1836.	4.7	91
198	Primary Neuroendocrine Neoplasms of the Breast: Case Series and Literature Review. Cancers, 2020, 12, 733.	3.7	17

#	Article	IF	Citations
199	Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease. Frontiers in Immunology, 2020, 11, 634409.	4.8	18
200	Serum levels of miR-223 but not miR-21 are decreased in patients with neuroendocrine tumors. PLoS ONE, 2020, 15, e0244504.	2.5	3
201	Pulmonary complications in patients with liver cirrhosis. Journal of Translational Internal Medicine, 2020, 8, 150-158.	2.5	19
202	A rare case of a patient with a high grade neuroendocrine tumor developing neutropenic sepsis after receiving PRRT combined with Capecitabine or Temozolomide: A case report. Molecular and Clinical Oncology, 2020, 14, 20.	1.0	4
203	Pulmonary infections in patients with and without hematological malignancies: diagnostic yield and safety of flexible bronchoscopy-a retrospective analysis. Journal of Thoracic Disease, 2020, 12, 4860-4867.	1.4	0
204	Editorial: prevalence, progression rates and mortality predictors of nonâ€alcoholic fatty liver disease reflected by German statutory health insurance data. Alimentary Pharmacology and Therapeutics, 2020, 52, 1412-1413.	3.7	1
205	Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications. Molecular Aspects of Medicine, 2019, 65, 2-15.	6.4	352
206	Machine perfusion for liver transplantation in the era of marginal organsâ€"New kids on the block. Liver International, 2019, 39, 228-249.	3.9	72
207	Whole-Body Plethysmography and Blood Gas Analysis in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Respiration, 2019, 97, 24-33.	2.6	7
208	Polypropylene mesh implantation for hernia repair causes myeloid cell–driven persistent inflammation. JCl Insight, 2019, 4, .	5.0	43
209	Use of nonselective \hat{I}^2 blockers after variceal eradication in cirrhotic patients undergoing secondary prophylaxis of esophageal variceal bleeding: a critical review of current evidence. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231986269.	2.5	6
210	An NF-kappaB- and IKK-Independent Function of NEMO Prevents Hepatocarcinogenesis by Suppressing Compensatory Liver Regeneration. Cancers, 2019, 11, 999.	3.7	13
211	Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. Hepatology, 2019, 70, 1424-1436.	7. 3	7 3
212	Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. Journal of Hepatology, 2019, 71, 823-833.	3.7	120
213	Evolving Trends in Machine Liver Perfusion: Comments on Clinical End Points and Selection Criteria. Gastroenterology, 2019, 157, 1166-1167.	1.3	20
214	Decreased CTRP3 Plasma Concentrations Are Associated with Sepsis and Predict Mortality in Critically Ill Patients. Diagnostics, 2019, 9, 63.	2.6	6
215	Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. International Journal of Molecular Sciences, 2019, 20, 3049.	4.1	110
216	A Combined Score of Circulating miRNAs Allows Outcome Prediction in Critically Ill Patients. Journal of Clinical Medicine, 2019, 8, 1644.	2.4	6

#	Article	IF	Citations
217	Sarcopenia Is a Negative Prognostic Factor in Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatic Malignancies. Cancers, 2019, 11, 1503.	3.7	35
218	Reply. Gastroenterology, 2019, 157, 1170-1171.	1.3	0
219	Modulating Myeloid Immune Cell Migration Using Multivalently Presented Monosaccharide Ligands for Advanced Immunotherapy. Advanced Therapeutics, 2019, 2, 1900145.	3.2	2
220	Association of serum albumin level with incidence and mortality of overt hepatic encephalopathy in cirrhosis during hospitalization. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481988130.	3.2	22
221	The Role of Adipokines as Circulating Biomarkers in Critical Illness and Sepsis. International Journal of Molecular Sciences, 2019, 20, 4820.	4.1	16
222	CX3CR1 Mediates the Development of Monocyte-Derived Dendritic Cells during Hepatic Inflammation. Cells, 2019, 8, 1099.	4.1	26
223	The CCR2+ Macrophage Subset Promotes Pathogenic Angiogenesis for Tumor Vascularization in Fibrotic Livers. Cellular and Molecular Gastroenterology and Hepatology, 2019, 7, 371-390.	4.5	71
224	Serum levels of miR-29, miR-122, miR-155 and miR-192 are elevated in patients with cholangiocarcinoma. PLoS ONE, 2019, 14, e0210944.	2.5	43
225	Single Cell RNA Sequencing Identifies Subsets of Hepatic Stellate Cells and Myofibroblasts in Liver Fibrosis. Cells, 2019, 8, 503.	4.1	153
226	Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nature Medicine, 2019, 25, 1054-1056.	30.7	773
227	Neutrophils are a main source of circulating suPAR predicting outcome in critical illness. Journal of Intensive Care, 2019, 7, 26.	2.9	39
228	Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism. JHEP Reports, 2019, 1, 30-43.	4.9	176
229	Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015. Zeitschrift Fur Gastroenterologie, 2019, 57, 584-592.	0.5	2
230	Elevated CTRP1 Plasma Concentration Is Associated with Sepsis and Pre-Existing Type 2 Diabetes Mellitus in Critically III Patients. Journal of Clinical Medicine, 2019, 8, 661.	2.4	14
231	Liver Macrophages: Old Dogmas and New Insights. Hepatology Communications, 2019, 3, 730-743.	4.3	256
232	Consistency of hepatocellular gadoxetic acid uptake in serial MRI examinations for evaluation of liver function. Abdominal Radiology, 2019, 44, 2759-2768.	2.1	10
233	PS-007-Differential therapeutic effects of pan- and single PPAR agonists on steatosis, inflammation, macrophage composition and fibrosis in a murine model of non-alcoholic steatohepatitis. Journal of Hepatology, 2019, 70, e8-e9.	3.7	1
234	Non-canonical HIF-1 stabilization contributes to intestinal tumorigenesis. Oncogene, 2019, 38, 5670-5685.	5.9	26

#	Article	IF	Citations
235	The prognostic role of lymphovascular invasion and lymph node metastasis in perihilar and intrahepatic cholangiocarcinoma. European Journal of Surgical Oncology, 2019, 45, 1468-1478.	1.0	50
236	miR-155 Predicts Long-Term Mortality in Critically Ill Patients Younger than 65 Years. Mediators of Inflammation, 2019, 2019, 1-8.	3.0	12
237	Prognostic Relevance of Altered Lymphocyte Subpopulations in Critical Illness and Sepsis. Journal of Clinical Medicine, 2019, 8, 353.	2.4	49
238	Creatine supplementation impairs airway inflammation in an experimental model of asthma involving P2 \tilde{A} — 7 receptor. European Journal of Immunology, 2019, 49, 928-939.	2.9	12
239	Liver fibrosis affects the targeting properties of drug delivery systems to macrophage subsets in vivo. Biomaterials, 2019, 206, 49-60.	11.4	22
240	Risk factors for remaining liver injury in patients with virological elimination of chronic hepatitis C. Zeitschrift Fur Gastroenterologie, 2019, 57, 139-147.	0.5	5
241	Mass migration to Europe: an opportunity for elimination of hepatitis B virus?. The Lancet Gastroenterology and Hepatology, 2019, 4, 315-323.	8.1	25
242	CXCR6 Inhibits Hepatocarcinogenesis by Promoting Natural Killer T- and CD4+ T-Cell–Dependent Control of Senescence. Gastroenterology, 2019, 156, 1877-1889.e4.	1.3	83
243	Platelet GPlb $\hat{\mathbf{l}}\pm$ is a mediator and potential interventional target for NASH and subsequent liver cancer. Nature Medicine, 2019, 25, 641-655.	30.7	259
244	The impact of technical and clinical factors on fecal microbiota transfer outcomes for the treatment of recurrent <i>Clostridioides difficile</i> infections in Germany. United European Gastroenterology Journal, 2019, 7, 716-722.	3.8	24
245	Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapyâ€"Data From the German Hepatitis C-Registry (DHC-R). Substance Abuse: Research and Treatment, 2019, 13, 117822181983584.	0.9	11
246	Elevated serum levels of bone sialoprotein (BSP) predict long-term mortality in patients with pancreatic adenocarcinoma. Scientific Reports, 2019, 9, 1489.	3.3	5
247	The co-inhibitory molecule PD-L1 contributes to regulatory T cell-mediated protection in murine crescentic glomerulonephritis. Scientific Reports, 2019, 9, 2038.	3.3	25
248	High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma. Carcinogenesis, 2019, 40, 947-955.	2.8	19
249	Nonâ€invasive structure–function assessment of the liver by 2D timeâ€harmonic elastography and the dynamic Liver MAximum capacity (LiMAx) test. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1611-1619.	2.8	16
250	Non-invasive assessment for alpha-1 antitrypsin deficiencyassociated liver disease: new insights on steatosis and fibrosis in Pi*ZZ carriers. Translational Gastroenterology and Hepatology, 2019, 4, 82-82.	3.0	2
251	Serum Levels of Kisspeptin Are Elevated in Patients with Pancreatic Cancer. Disease Markers, 2019, 2019, 1-8.	1.3	7
252	How effective and how durable is DAAâ€therapy in HCVâ€infected drug users?. Liver International, 2019, 39, 2238-2239.	3.9	3

#	Article	IF	Citations
253	Serum Levels of miR-143 Predict Survival in Critically III Patients. Disease Markers, 2019, 2019, 1-10.	1.3	10
254	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 394, 2184-2196.	13.7	818
255	Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry. European Journal of Gastroenterology and Hepatology, 2019, 31, 230-240.	1.6	8
256	Elevated MR-proANP plasma concentrations are associated with sepsis and predict mortality in critically ill patients. Journal of Translational Medicine, 2019, 17, 415.	4.4	22
257	Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology, 2019, 69, 2672-2682.	7.3	1,203
258	CXCR6 protects from inflammation and fibrosis in NEMOLPC-KO mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 391-402.	3.8	14
259	Clinical Practice Guidelines of the European Association for the study of the Liver – Advancing methodology but preserving practicability. Journal of Hepatology, 2019, 70, 5-7.	3.7	31
260	Relevance of Autophagy in Parenchymal and Non-Parenchymal Liver Cells for Health and Disease. Cells, 2019, 8, 16.	4.1	58
261	Response to the "Letter to the editor regarding article, 'Highâ€mobility group box 1 as a biomarker in critically ill patients'.― Journal of Clinical Laboratory Analysis, 2019, 33, e22820.	2.1	0
262	Characterization and Triggers of Dyspnea in Patients with Chronic Obstructive Pulmonary Disease or Chronic Heart Failure: Effects of Weather and Environment. Lung, 2019, 197, 21-28.	3.3	7
263	Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register). European Journal of Gastroenterology and Hepatology, 2019, 31, 1424-1431.	1.6	5
264	Endobronchial ultrasound-guided transbronchial needle aspiration under general anesthesia versus bronchoscopist-directed deep sedation: A retrospective analysis. Endoscopic Ultrasound, 2019, 8, 204.	1.5	17
265	The Janus-like Face of IL-4Rα in Macrophages during Liver Fibrosis. EBioMedicine, 2018, 29, 7-8.	6.1	0
266	Glucocorticoid-loaded liposomes induce a pro-resolution phenotype in human primary macrophages to support chronic wound healing. Biomaterials, 2018, 178, 481-495.	11.4	50
267	Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis. Expert Opinion on Investigational Drugs, 2018, 27, 301-311.	4.1	95
268	Dynamic plasticity of macrophage functions in diseased liver. Cellular Immunology, 2018, 330, 175-182.	3.0	44
269	Targeting and Modulation of Liver Myeloid Immune Cells by Hard‧hell Microbubbles. Advanced Biology, 2018, 2, 1800002.	3.0	6
270	Liver inflammation and regeneration in drug-induced liver injury: sex matters!. Clinical Science, 2018, 132, 609-613.	4.3	25

#	Article	IF	CITATIONS
271	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. The Lancet Gastroenterology and Hepatology, 2018, 3, 383-403.	8.1	1,241
272	New Insights on the Role of Kupffer Cells in Liver Transplantation. Transplantation, 2018, 102, 896-897.	1.0	6
273	«The times they are a'changin'» – Positioning the European Association for the Study of the Liver in the changing landscape of hepatology. Journal of Hepatology, 2018, 68, 873-875.	3.7	9
274	Repair macrophages in acute liver failure. Gut, 2018, 67, 202-203.	12.1	14
275	A randomized, placeboâ€controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology, 2018, 67, 1754-1767.	7.3	528
276	Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. Hepatology, 2018, 67, 1270-1283.	7.3	388
277	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. Gut, 2018, 67, 1517-1524.	12.1	42
278	Adapted Immune Responses of Myeloid-Derived Cells in Fatty Liver Disease. Frontiers in Immunology, 2018, 9, 2418.	4.8	31
279	Nebulization versus standard application for topical anaesthesia during flexible bronchoscopy under moderate sedation $\hat{a} \in \mathbb{C}$ a randomized controlled trial. Respiratory Research, 2018, 19, 227.	3.6	10
280	Circulating Levels of Osteopontin Predict Patients' Outcome after Resection of Colorectal Liver Metastases. Journal of Clinical Medicine, 2018, 7, 390.	2.4	12
281	microRNA 193a-5p Regulates Levels of Nucleolar- and Spindle-Associated Protein 1 to Suppress Hepatocarcinogenesis. Gastroenterology, 2018, 155, 1951-1966.e26.	1.3	86
282	The Role of Radiologic Modalities in Diagnosing Nonalcoholic Steatohepatitis (NASH) and Fibrosis. Current Hepatology Reports, 2018, 17, 324-335.	0.9	8
283	An update on the recent advances in antifibrotic therapy. Expert Review of Gastroenterology and Hepatology, 2018, 12, 1143-1152.	3.0	60
284	Purinergic Signaling: A New Pharmacological Target Against Viruses?. Trends in Pharmacological Sciences, 2018, 39, 926-936.	8.7	18
285	Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts. F1000Research, 2018, 7, 921.	1.6	80
286	Serum levels of kisspeptin are elevated in critically ill patients. PLoS ONE, 2018, 13, e0206064.	2.5	8
287	Effects of aging on liver microcirculatory function and sinusoidal phenotype. Aging Cell, 2018, 17, e12829.	6.7	92
288	Visfatin Serum Levels Predict Mortality in Critically III Patients. Disease Markers, 2018, 2018, 1-8.	1.3	12

#	Article	IF	Citations
289	Clinical relevance of copeptin plasma levels as a biomarker of disease severity and mortality in critically ill patients. Journal of Clinical Laboratory Analysis, 2018, 32, e22614.	2.1	20
290	Elevated Serum Levels of Mixed Lineage Kinase Domain-Like Protein Predict Survival of Patients during Intensive Care Unit Treatment. Disease Markers, 2018, 2018, 1-8.	1.3	16
291	High Circulating Caspase-Cleaved Keratin 18 Fragments (M30) Indicate Short-Term Mortality in Critically Ill Patients. Disease Markers, 2018, 2018, 1-8.	1.3	8
292	Add-on Therapy for Symptomatic Asthma despite Long-Acting Beta-Agonists/Inhaled Corticosteroid. Tuberculosis and Respiratory Diseases, 2018, 81, 1.	1.8	5
293	Differential Roles of Tumor Necrosis Factor Ligand Superfamily Members as Biomarkers in Pancreatic Cancer. Journal of Clinical Medicine, 2018, 7, 175.	2.4	5
294	Sleep-disordered breathing in patients with newly diagnosed lung cancer. BMC Pulmonary Medicine, 2018, 18, 72.	2.0	32
295	Elevated serum levels of bone sialoprotein during ICU treatment predict long-term mortality in critically ill patients. Scientific Reports, 2018, 8, 9750.	3.3	3
296	IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies. International Journal of Molecular Sciences, 2018, 19, 1766.	4.1	38
297	Fatal Hemorrhage due to an Aortic Pseudoaneurysm Related to an Endobronchial Coil. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 670-671.	5.6	0
298	Transient portal vein thrombosis in liver cirrhosis. BMC Medicine, 2018, 16, 83.	5.5	51
299	Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany. Journal of Hepatology, 2018, 69, 982-984.	3.7	22
300	Glucagon-Like Peptide 1 and Its Cleavage Products Are Renoprotective in Murine Diabetic Nephropathy. Diabetes, 2018, 67, 2410-2419.	0.6	38
301	Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry. Drugs and Aging, 2018, 35, 843-857.	2.7	17
302	High mobility group box 1 as a biomarker in critically ill patients. Journal of Clinical Laboratory Analysis, $2018,32,e22584.$	2.1	15
303	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. Journal of Hepatology, 2018, 69, 896-904.	3.7	1,157
304	Serum levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of colorectal liver metastases. Oncotarget, 2018, 9, 27027-27038.	1.8	19
305	Management of hepatitis C virus infection in the Asia-Pacific region: an update. The Lancet Gastroenterology and Hepatology, 2017, 2, 52-62.	8.1	45
306	Targeting hepatic macrophages to treat liver diseases. Journal of Hepatology, 2017, 66, 1300-1312.	3.7	712

#	Article	IF	Citations
307	Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy. Journal of Hepatology, 2017, 67, 246-254.	3.7	52
308	EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of Hepatology, 2017, 67, 370-398.	3.7	3,803
309	Targeting CCl4â€induced liver fibrosis by RNA interference–mediated inhibition of cyclin E1 in mice. Hepatology, 2017, 66, 1242-1257.	7.3	46
310	GLP-1 Levels Predict Mortality in Patients with Critical Illness as Well as End-Stage Renal Disease. American Journal of Medicine, 2017, 130, 833-841.e3.	1.5	44
311	Liver macrophages in tissue homeostasis and disease. Nature Reviews Immunology, 2017, 17, 306-321.	22.7	935
312	Liver â€" guardian, modifier and target of sepsis. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 55-66.	17.8	371
313	The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism. Diabetes, Obesity and Metabolism, 2017, 19, 496-508.	4.4	26
314	Polymeric Selectin Ligands Mimicking Complex Carbohydrates: From Selectin Binders to Modifiers of Macrophage Migration. Angewandte Chemie - International Edition, 2017, 56, 1416-1421.	13.8	41
315	RIPK1 Suppresses a TRAF2-Dependent Pathway to Liver Cancer. Cancer Cell, 2017, 31, 94-109.	16.8	115
316	Interleukin-33 in the pathogenesis of liver fibrosis: alarming ILC2 and hepatic stellate cells. Cellular and Molecular Immunology, 2017, 14, 143-145.	10.5	33
317	One-Step Fabrication of Biocompatible Multifaceted Nanocomposite Gels and Nanolayers. Biomacromolecules, 2017, 18, 386-397.	5.4	17
318	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nature Genetics, 2017, 49, 269-273.	21.4	230
319	Combining <scp>GP</scp> 73 with liver stiffness measurements: A proofâ€ofâ€concept for nonâ€invasive fibrosis assessment in antiviralâ€naà ve <scp>HBV</scp> patients. Liver International, 2017, 37, 1605-1607.	3.9	5
320	Hypothermic oxygenated machine perfusion (HOPE) for orthotopic liver transplantation of human liver allografts from extended criteria donors (ECD) in donation after brain death (DBD): a prospective multicentre randomised controlled trial (HOPE ECD-DBD). BMJ Open, 2017, 7, e017558.	1.9	66
321	Isolation and Culture of Primary Murine Hepatic Stellate Cells. Methods in Molecular Biology, 2017, 1627, 165-191.	0.9	45
322	Immunomodulatory Therapy of Inflammatory Liver Disease Using Selectin-Binding Glycopolymers. ACS Nano, 2017, 11, 9689-9700.	14.6	36
323	Macrophages in Nonalcoholic Fatty Liver Disease: A Role Model of Pathogenic Immunometabolism. Seminars in Liver Disease, 2017, 37, 189-197.	3.6	48
324	A not so easy genotypeâ€"striking regional differences in <scp>SOF</scp> / <scp>RBV</scp> treatment responses in <scp>HCV GT</scp> 2. Liver International, 2017, 37, 1253-1254.	3.9	0

#	Article	IF	Citations
325	CX3CR1 modulates the anti-inflammatory activity of hepatic dendritic cells in response to acute liver injury. Clinical Science, 2017, 131, 2289-2301.	4.3	10
326	Polymere Selectinliganden als komplexe Glykomimetika: von Selectinbindung bis zur Modifizierung der Makrophagenmigration. Angewandte Chemie, 2017, 129, 1438-1443.	2.0	2
327	Synthetic integrin-binding immune stimulators target cancer cells and prevent tumor formation. Scientific Reports, 2017, 7, 17592.	3.3	9
328	CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma. Scientific Reports, 2017, 7, 16975.	3.3	65
329	Fibrosis imaging: Current concepts and future directions. Advanced Drug Delivery Reviews, 2017, 121, 9-26.	13.7	110
330	miR-1224 inhibits cell proliferation in acute liver failure by targeting the antiapoptotic gene Nfib. Journal of Hepatology, 2017, 67, 966-978.	3.7	64
331	Optimizing inhalation technique using web-based videos in obstructive lung diseases. Respiratory Medicine, 2017, 129, 140-144.	2.9	27
332	Biomarkers and Liver Disease: Can We Predict Decompensation with suPAR?. Current Hepatology Reports, 2017, 16, 164-168.	0.9	0
333	C-terminal proendothelin-1 (CT-proET-1) is associated with organ failure and predicts mortality in critically ill patients. Journal of Intensive Care, 2017, 5, 25.	2.9	23
334	Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma. Journal of Hepatology, 2017, 67, 749-757.	3.7	64
335	Targeting distinct myeloid cell populations inÂvivo using polymers, liposomes and microbubbles. Biomaterials, 2017, 114, 106-120.	11.4	63
336	From NAFLD to HCC: Is ILâ€17 the crucial link?. Hepatology, 2017, 65, 739-741.	7.3	9
337	Gold Nanocarriers for Macrophageâ€Targeted Therapy of Human Immunodeficiency Virus. Macromolecular Bioscience, 2017, 17, 1600359.	4.1	20
338	Relevance of serum sclerostin concentrations in critically ill patients. Journal of Critical Care, 2017, 37, 38-44.	2.2	7
339	Regardless of etiology, progressive renal disease causes ultrastructural and functional alterations of peritubular capillaries. Kidney International, 2017, 91, 70-85.	5.2	122
340	A liver nodule in a patient transplanted for primary sclerosing cholangitis: an interdisciplinary diagnostic approach. Zeitschrift Fur Gastroenterologie, 2017, 55, 56-62.	0.5	3
341	HBsAg mutations related to occult hepatitis B virus infection in HIVâ€positive patients result in a reduced secretion and conformational changes of HBsAg. Journal of Medical Virology, 2017, 89, 246-256.	5.0	18
342	Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials. Liver International, 2017, 37, 205-211.	3.9	37

#	Article	IF	Citations
343	Elevated Soluble Urokinase Plasminogen Activator Receptor and Proenkephalin Serum Levels Predict the Development of Acute Kidney Injury after Cardiac Surgery. International Journal of Molecular Sciences, 2017, 18, 1662.	4.1	50
344	Growth Differentiation Factor-15 Is a Predictor of Mortality in Critically Ill Patients with Sepsis. Disease Markers, 2017, 2017, 1-10.	1.3	54
345	Analogosedation during flexible bronchoscopy using a combination of midazolam, propofol and fentanyl $\hat{a}\in$ A retrospective analysis. PLoS ONE, 2017, 12, e0175394.	2.5	14
346	Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury. PLoS ONE, 2017, 12, e0184694.	2.5	49
347	Do we still need pharmacological stress ulcer prophylaxis at the ICU?. Journal of Thoracic Disease, 2017, 9, 4201-4204.	1.4	4
348	Immune surveillance of liver cancer in non-alcoholic fatty liver disease: excess lipids cause CD4 T-cells loss and promote hepatocellular carcinoma development. Hepatobiliary Surgery and Nutrition, 2016, 5, 433-437.	1.5	13
349	Elevated Omentin Serum Levels Predict Long-Term Survival in Critically Ill Patients. Disease Markers, 2016, 2016, 1-9.	1.3	12
350	Pharmacological Intervention in Hepatic Stellate Cell Activation and Hepatic Fibrosis. Frontiers in Pharmacology, 2016, 7, 33.	3.5	81
351	Prevention of stress-related ulcer bleeding at the intensive care unit: Risks and benefits of stress ulcer prophylaxis. World Journal of Critical Care Medicine, 2016, 5, 57.	1.8	53
352	Treatment for hepatitis B in patients with drug resistance. Annals of Translational Medicine, 2016, 4, 334-334.	1.7	22
353	Chemokine (Câ€C motif) receptor 2–positive monocytes aggravate the early phase of acetaminophenâ€induced acute liver injury. Hepatology, 2016, 64, 1667-1682.	7.3	271
354	Lipocalinâ€2 (NGAL/LCN2), a "helpâ€me―signal in organ inflammation. Hepatology, 2016, 63, 669-671.	7.3	53
355	Iron Parameters Determine the Prognosis of Critically Ill Patients*. Critical Care Medicine, 2016, 44, 1049-1058.	0.9	86
356	Liver transplantation in Germany. Liver Transplantation, 2016, 22, 1136-1142.	2.4	87
357	Receptor interacting protein kinase 1 (RIPK1) in hepatocytes does not mediate murine acetaminophen toxicity. Hepatology, 2016, 64, 306-308.	7.3	26
358	Serum levels of S100A6 are unaltered in patients with resectable cholangiocarcinoma. Clinical and Translational Medicine, 2016, 5, 39.	4.0	14
359	Antiviral Therapy in Patients with Viral Hepatitis and Hepatocellular Carcinoma: Indications and Prognosis. Visceral Medicine, 2016, 32, 121-126.	1.3	14
360	Liver Fibrosis: From Pathogenesis to Novel Therapies. Digestive Diseases, 2016, 34, 410-422.	1.9	128

#	Article	IF	Citations
361	Stromal cell-derived factor-1 (SDF-1) as a target in liver diseases. American Journal of Physiology - Renal Physiology, 2016, 311, G203-G209.	3.4	7 5
362	Down-regulation of <i>miR-192-5p</i> protects from oxidative stress-induced acute liver injury. Clinical Science, 2016, 130, 1197-1207.	4.3	59
363	Soluble urokinase plasminogen activator receptor (suPAR): Its relation to neurological outcome in patients with survived cardiac arrest. IJC Metabolic & Endocrine, 2016, 12, 8-13.	0.5	1
364	lîºB kinaseα/β control biliary homeostasis and hepatocarcinogenesis in mice by phosphorylating the cellâ€death mediator receptorâ€interacting protein kinase 1. Hepatology, 2016, 64, 1217-1231.	7.3	54
365	The necroptosis-inducing kinase RIPK3 dampens adipose tissue inflammation and glucose intolerance. Nature Communications, 2016, 7, 11869.	12.8	68
366	Liver fibrosis: Which mechanisms matter?. Clinical Liver Disease, 2016, 8, 94-99.	2.1	15
367	Histidineâ€rich glycoprotein promotes macrophage activation and inflammation in chronic liver disease. Hepatology, 2016, 63, 1310-1324.	7.3	77
368	IL-23 prevents IL-13-dependent tissue repair associated with Ly6C lo monocytes in Entamoeba histolytica -induced liver damage. Journal of Hepatology, 2016, 64, 1147-1157.	3.7	18
369	Immunology in the liver — from homeostasis to disease. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 88-110.	17.8	810
370	M-CSF and GM-CSF Receptor Signaling Differentially Regulate Monocyte Maturation and Macrophage Polarization in the Tumor Microenvironment. Cancer Research, 2016, 76, 35-42.	0.9	184
371	Enhanced expression of c-myc in hepatocytes promotes initiation and progression of alcoholic liver disease. Journal of Hepatology, 2016, 64, 628-640.	3.7	29
372	Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies. Cellular and Molecular Immunology, 2016, 13, 316-327.	10.5	414
373	Tiny RNA with great effects: miR-155 in alcoholic liver disease. Journal of Hepatology, 2016, 64, 1214-1216.	3.7	28
374	Role of chemokine pathways in hepatobiliary cancer. Cancer Letters, 2016, 379, 173-183.	7.2	64
375	Serum Levels of TNF Receptor Ligands Are Dysregulated in Sepsis and Predict Mortality in Critically Ill Patients. PLoS ONE, 2016, 11, e0153765.	2.5	15
376	Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis. Scientific Reports, 2015, 5, 12931.	3.3	127
377	Long Term Intravital Multiphoton Microscopy Imaging of Immune Cells in Healthy and Diseased Liver Using CXCR6.Gfp Reporter Mice. Journal of Visualized Experiments, 2015, , .	0.3	26
378	Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis. Journal of Visualized Experiments, 2015, , .	0.3	187

#	Article	IF	CITATIONS
379	<scp>miR</scp> â€30c and <scp>miR</scp> â€193 are a part of the <scp>TGF</scp> â€î²â€dependent regulatory network controlling extracellular matrix genes in liver fibrosis. Journal of Digestive Diseases, 2015, 16, 513-524.	1.5	57
380	Persistently elevated osteopontin serum levels predict mortality in critically ill patients. Critical Care, 2015, 19, 271.	5.8	40
381	Small heterodimer partner (SHP) links hepatitis C and liver fibrosis: a small protein on the big stage. Liver International, 2015, 35, 2218-2221.	3.9	2
382	CX3CR1 is a gatekeeper for intestinal barrier integrity in mice: Limiting steatohepatitis by maintaining intestinal homeostasis. Hepatology, 2015, 62, 1405-1416.	7.3	94
383	Differential Induction of Ly6G and Ly6C Positive Myeloid Derived Suppressor Cells in Chronic Kidney and Liver Inflammation and Fibrosis. PLoS ONE, 2015, 10, e0119662.	2.5	43
384	Isolation and Time Lapse Microscopy of Highly Pure Hepatic Stellate Cells. Analytical Cellular Pathology, 2015, 2015, 1-13.	1.4	22
385	Circulating MicroRNA-223 Serum Levels Do Not Predict Sepsis or Survival in Patients with Critical Illness. Disease Markers, 2015, 2015, 1-10.	1.3	34
386	The Roles of CXCL16 and CXCR6 in Liver Inflammation and Fibrosis. Current Pathobiology Reports, 2015, 3, 283-290.	3.4	7
387	CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt. Journal of Hepatology, 2015, 62, 332-339.	3.7	58
388	CC Chemokine Ligand 18 in ANCA-Associated Crescentic GN. Journal of the American Society of Nephrology: JASN, 2015, 26, 2105-2117.	6.1	38
389	Mechanisms of liver fibrosis resolution. Journal of Hepatology, 2015, 63, 1038-1039.	3.7	150
390	In search of the magic bullet: can liver inflammation and fibrosis be reversed with medications?. Expert Review of Gastroenterology and Hepatology, 2015, 9, 1139-1141.	3.0	6
391	Ly6C- Monocytes Regulate Parasite-Induced Liver Inflammation by Inducing the Differentiation of Pathogenic Ly6C+ Monocytes into Macrophages. PLoS Pathogens, 2015, 11, e1004873.	4.7	45
392	Molecular response of liver sinusoidal endothelial cells on hydrogels. Materials Science and Engineering C, 2015, 51, 64-72.	7.3	12
393	Liver inflammation abrogates immunological tolerance induced by Kupffer cells. Hepatology, 2015, 62, 279-291.	7.3	304
394	Biomarker and Therapeutic Potential of CSF1 in Acute Liver Failure. Gastroenterology, 2015, 149, 1675-1678.	1.3	1
395	Influence of effective noninvasive positive pressure ventilation on inflammatory and cardiovascular biomarkers in stable hypercapnic COPD patients. Respiratory Medicine, 2015, 109, 1300-1304.	2.9	13
396	A rare case of HBV genotype fluctuation (shifting and reversion) after liver transplantation. Journal of Clinical Virology, 2015, 71, 93-97.	3.1	5

#	Article	IF	CITATIONS
397	Cyclic adenosine monophosphate–responsive element modulator alpha overexpression impairs function of hepatic myeloidâ€derived suppressor cells and aggravates immuneâ€mediated hepatitis in mice. Hepatology, 2015, 61, 990-1002.	7.3	31
398	Elevated miRâ€122 serum levels are an independent marker of liver injury in inflammatory diseases. Liver International, 2015, 35, 1172-1184.	3.9	98
399	Fluorescent cell-traceable dexamethasone-loaded liposomes for the treatment of inflammatory liver diseases. Biomaterials, 2015, 37, 367-382.	11.4	115
400	Emerging roles of myeloid derived suppressor cells in hepatic inflammation and fibrosis. World Journal of Gastrointestinal Pathophysiology, 2015, 6, 43.	1.0	41
401	Molecular interactions between hepatitis B virus and delta virus. World Journal of Virology, 2015, 4, 36.	2.9	23
402	Genomic Diversity of Hepatitis B Virus Infection Associated With Fulminant Hepatitis B Development. Hepatitis Monthly, 2015, 15, e29477.	0.2	26
403	Critically Ill Patients and Circulating Amino-Terminal Pro-C-Type Natriuretic Peptide., 2015,, 143-151.		O
404	Healing the scars of life-targeting redox imbalance in fibrotic disorders of the elderly. Annals of Translational Medicine, 2015, 3, S13.	1.7	3
405	Authors' response: impact of renal replacement therapy on osteopontin levels in critically ill patients. Critical Care, 2015, 19, 426.	5.8	1
406	Distinct Patterns of IgG and IgA against Food and Microbial Antigens in Serum and Feces of Patients with Inflammatory Bowel Diseases. PLoS ONE, 2014, 9, e106750.	2.5	36
407	GLP-1 Secretion Is Increased by Inflammatory Stimuli in an IL-6–Dependent Manner, Leading to Hyperinsulinemia and Blood Glucose Lowering. Diabetes, 2014, 63, 3221-3229.	0.6	155
408	Variceal Bleeding in Liver Cirrhosis at the ICU. Critical Care Medicine, 2014, 42, 2639-2640.	0.9	2
409	Chemokine receptor CCR6-dependent accumulation of $\hat{l}^3\hat{l}$ T cells in injured liver restricts hepatic inflammation and fibrosis. Hepatology, 2014, 59, 630-642.	7.3	180
410	Corrigendum to "Factor VII activating protease (FSAP) exerts anti-inflammatory and anti-fibrotic effects in liver fibrosis in mice and men―[J Hepatol 2013;58:104–111]. Journal of Hepatology, 2014, 61, 967.	3.7	O
411	Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte) Tj ETQq1 1 0.784314 rgBT Ly-6C ⁺ macrophage infiltration in mice. Hepatology, 2014, 59, 1060-1072.	Overlock 7.3	2 10 Tf 50 1 216
412	A positive feedback loop between <scp>RIP</scp> 3 and <scp>JNK</scp> controls nonâ€alcoholic steatohepatitis. EMBO Molecular Medicine, 2014, 6, 1062-1074.	6.9	253
413	Critically III Patients and Circulating Amino-Terminal Pro-C-Type Natriuretic Peptide., 2014,, 1-10.		O
414	Levels of Circulating miR-133a Are Elevated in Sepsis and Predict Mortality in Critically Ill Patients. Critical Care Medicine, 2014, 42, 1096-1104.	0.9	111

#	Article	IF	Citations
415	Molecular identification of hepatitis B virus genotypes/subgenotypes: Revised classification hurdles and updated resolutions. World Journal of Gastroenterology, 2014, 20, 7152.	3.3	154
416	Translation control of TAK1 mRNA by hnRNP K modulates LPS-induced macrophage activation. Rna, 2014, 20, 899-911.	3.5	31
417	Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor (su <scp>PAR</scp>) in acute liver failure. Liver International, 2014, 34, 1330-1339.	3.9	44
418	Macrophage heterogeneity in liver injury and fibrosis. Journal of Hepatology, 2014, 60, 1090-1096.	3.7	805
419	Roles for Chemokines in Liver Disease. Gastroenterology, 2014, 147, 577-594.e1.	1.3	634
420	CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. Gut, 2014, 63, 1960-1971.	12.1	247
421	The impact of elevated serum IgG4 levels in patients with primary sclerosing cholangitis. Digestive and Liver Disease, 2014, 46, 903-908.	0.9	42
422	Liposomal encapsulation of dexamethasone modulates cytotoxicity, inflammatory cytokine response, and migratory properties of primary human macrophages. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 1209-1220.	3.3	80
423	Administration of proton pump inhibitors in critically ill medical patients is associated with increased risk of developing Clostridium difficile–associated diarrhea. Journal of Critical Care, 2014, 29, 696.e11-696.e15.	2.2	84
424	Interleukins in chronic liver disease: lessons learned from experimental mouse models. Clinical and Experimental Gastroenterology, 2014, 7, 297.	2.3	99
425	Pharmacological Inhibition of the Chemokine CXCL16 Diminishes Liver Macrophage Infiltration and Steatohepatitis in Chronic Hepatic Injury. PLoS ONE, 2014, 9, e112327.	2.5	63
426	Immune mechanisms in acetaminophen-induced acute liver failure. Hepatobiliary Surgery and Nutrition, 2014, 3, 331-43.	1.5	110
427	Therapeutic targeting of liver inflammation and fibrosis by nanomedicine. Hepatobiliary Surgery and Nutrition, 2014, 3, 364-76.	1.5	66
428	Cellular and molecular functions of hepatic stellate cells in inflammatory responses and liver immunology. Hepatobiliary Surgery and Nutrition, 2014, 3, 344-63.	1.5	145
429	Liver immunology: new perspectives. Hepatobiliary Surgery and Nutrition, 2014, 3, 330.	1.5	2
430	Role of gamma-delta T cells in liver inflammation and fibrosis. World Journal of Gastrointestinal Pathophysiology, 2014, 5, 107.	1.0	61
431	Balance of inflammatory pathways and interplay of immune cells in the liver during homeostasis and injury. EXCLI Journal, 2014, 13, 67-81.	0.7	20
432	Serum sodium based modification of the MELD does not improve prediction of outcome in acute liver failure. BMC Gastroenterology, 2013, 13, 58.	2.0	13

#	Article	IF	CITATIONS
433	From NAFLD to NASH to fibrosis to HCC: Role of dendritic cell populations in the liver. Hepatology, 2013, 58, 494-496.	7.3	25
434	Elevated asymmetric dimethylarginine levels predict short- and long-term mortality risk in critically ill patients. Journal of Critical Care, 2013, 28, 947-953.	2.2	43
435	Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. Fibrogenesis and Tissue Repair, 2013, 6, 19.	3.4	256
436	Overexpression of c-myc in hepatocytes promotes activation of hepatic stellate cells and facilitates the onset of liver fibrosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1765-1775.	3.8	67
437	RIP3 Inhibits Inflammatory Hepatocarcinogenesis but Promotes Cholestasis by Controlling Caspase-8-and JNK-Dependent Compensatory Cell Proliferation. Cell Reports, 2013, 4, 776-790.	6.4	124
438	YB-1 Is an Early and Central Mediator of Bacterial and Sterile Inflammation In Vivo. Journal of Immunology, 2013, 191, 2604-2613.	0.8	57
439	Serum concentrations of A Proliferation-Inducing Ligand (APRIL) are elevated in sepsis and predict mortality in critically ill patients. Journal of Critical Care, 2013, 28, 882.e1-882.e11.	2.2	10
440	miR-133a mediates TGF- \hat{l}^2 -dependent derepression of collagen synthesis in hepatic stellate cells during liver fibrosis. Journal of Hepatology, 2013, 58, 736-742.	3.7	110
441	Factor VII activating protease (FSAP) exerts anti-inflammatory and anti-fibrotic effects in liver fibrosis in mice and men. Journal of Hepatology, 2013, 58, 104-111.	3.7	32
442	Protective effects of lipocalin-2 (LCN2) in acute liver injury suggest a novel function in liver homeostasis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 660-673.	3.8	119
443	Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nature Genetics, 2013, 45, 670-675.	21.4	339
444	U6 is unsuitable for normalization of serum miRNA levels in patients with sepsis or liver fibrosis. Experimental and Molecular Medicine, 2013, 45, e42-e42.	7.7	139
445	Regulation and Prognostic Relevance of Symmetric Dimethylarginine Serum Concentrations in Critical Illness and Sepsis. Mediators of Inflammation, 2013, 2013, 1-8.	3.0	28
446	TNFα-Mediated Liver Destruction by Kupffer Cells and Ly6Chi Monocytes during Entamoeba histolytica Infection. PLoS Pathogens, 2013, 9, e1003096.	4.7	78
447	Chemokine Receptor CXCR6-Dependent Hepatic NK T Cell Accumulation Promotes Inflammation and Liver Fibrosis. Journal of Immunology, 2013, 190, 5226-5236.	0.8	219
448	2013, 36, .	0.6	2
449	Frequency and Phenotype of Human Circulating and Intrahepatic Natural Killer Cell Subsets Is Differentially Regulated according to Stage of Chronic Liver Disease. Digestion, 2013, 88, 1-16.	2.3	9
450	Role of lymphocytes in liver cancer. Oncolmmunology, 2013, 2, e26468.	4.6	66

#	Article	IF	Citations
451	Elastin-based molecular MRI of liver fibrosis. Hepatology, 2013, 58, 1517-1518.	7.3	38
452	Circulating MicroRNA-150 Serum Levels Predict Survival in Patients with Critical Illness and Sepsis. PLoS ONE, 2013, 8, e54612.	2.5	138
453	Influence of the CXCL1 rs4074 A Allele on Alcohol Induced Cirrhosis and HCC in Patients of European Descent. PLoS ONE, 2013, 8, e80848.	2.5	18
454	LETTER TO THE EDITOR: Associations between Hepatitis B Virus Core Gene Mutations, Immune Escape and Clinical Presentation. Clinical Laboratory, 2013, 59, 1097-9; author reply 1100-1.	0.5	0
455	Met-CCL5 modifies monocyte subpopulations during liver fibrosis regression. International Journal of Clinical and Experimental Pathology, 2013, 6, 678-85.	0.5	14
456	Eat more carrots? Dampening cell death in ethanol-induced liver fibrosis by \hat{l}^2 -carotene. Hepatobiliary Surgery and Nutrition, 2013, 2, 248-51.	1.5	1
457	Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Liver International, 2012, 32, 500-509.	3.9	68
458	Impact of Drug-Resistance Polymerase Mutations on the Replication of HBeAg-Positive and HBeAg-Negative Hepatitis B Virus Strains in Vitro. Hepatitis Monthly, 2012, 12, 357-360.	0.2	4
459	Distinct anti-tumoral functions of adaptive immune cells in liver cancer. Oncolmmunology, 2012, 1, 937-939.	4.6	6
460	Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. Gut, 2012, 61, 1733-1743.	12.1	159
461	CREMα overexpression decreases IL-2 production, induces a TH17 phenotype and accelerates autoimmunity. Journal of Molecular Cell Biology, 2012, 4, 121-123.	3.3	34
462	Functional Role of Monocytes and Macrophages for the Inflammatory Response in Acute Liver Injury. Frontiers in Physiology, 2012, 3, 56.	2.8	204
463	Peptide-Functionalized Gold Nanorods Increase Liver Injury in Hepatitis. ACS Nano, 2012, 6, 8767-8777.	14.6	137
464	Effects of nanoparticle surface-coupled peptides, functional endgroups, and charge on intracellular distribution and functionality of human primary reticuloendothelial cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2012, 8, 1282-1292.	3.3	40
465	Two Distinct Types of Langerhans Cells Populate the Skin during Steady State and Inflammation. Immunity, 2012, 37, 905-916.	14.3	176
466	Risk stratification and triage in the emergency department: has this become â€̃su <scp>PAR</scp> ' easy?. Journal of Internal Medicine, 2012, 272, 243-246.	6.0	14
467	Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Medicine, 2012, 38, 1418-1428.	8.2	474
468	Hyaluronan serum concentrations are elevated in critically ill patients and associated with disease severity. Clinical Biochemistry, 2012, 45, 82-87.	1.9	47

#	Article	IF	Citations
469	Serum NT-proCNP concentrations are elevated in patients with chronic liver diseases and associated with complications and unfavorable prognosis of cirrhosis. Clinical Biochemistry, 2012, 45, 429-435.	1.9	13
470	Etiologies and Outcomes of Acute Liver Failure in Germany. Clinical Gastroenterology and Hepatology, 2012, 10, 664-669.e2.	4.4	120
471	Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut, 2012, 61, 416-426.	12.1	485
472	Betaâ€glucosidase 2 knockout mice with increased glucosylceramide show impaired liver regeneration. Liver International, 2012, 32, 1354-1362.	3.9	22
473	Update on hepatic stellate cells: pathogenic role in liver fibrosis and novel isolation techniques. Expert Review of Gastroenterology and Hepatology, 2012, 6, 67-80.	3.0	153
474	Elevated circulating soluble interleukin-2 receptor in patients with chronic liver diseases is associated with non-classical monocytes. BMC Gastroenterology, 2012, 12, 38.	2.0	48
475	Micro-RNA Profiling in Human Serum Reveals Compartment-Specific Roles of miR-571 and miR-652 in Liver Cirrhosis. PLoS ONE, 2012, 7, e32999.	2.5	92
476	Cyclin E1 controls proliferation of hepatic stellate cells and is essential for liver fibrogenesis in mice. Hepatology, 2012, 56, 1140-1149.	7.3	50
477	Functional role of intrahepatic monocyte subsets for the progression of liver inflammation and liver fibrosis in vivo. Fibrogenesis and Tissue Repair, 2012, 5, S27.	3.4	79
478	Hepatic macrophage migration and differentiation critical for liver fibrosis is mediated by the chemokine receptor C-C motif chemokine receptor 8 in mice. Hepatology, 2012, 55, 898-909.	7.3	144
479	Primary Cultures of Glomerular Parietal Epithelial Cells or Podocytes with Proven Origin. PLoS ONE, 2012, 7, e34907.	2.5	55
480	Molecular and clinical aspects of hepatitis D virus infections. World Journal of Virology, 2012, 1, 71.	2.9	20
481	Prognostic value of circulating amino-terminal pro-C-type natriuretic peptide in critically ill patients. Critical Care, 2011, 15, R45.	5.8	49
482	Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Critical Care, 2011, 15, R63.	5.8	248
483	Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature, 2011, 479, 547-551.	27.8	1,208
484	Expression of the megalin C-terminal fragment by macrophages during liver fibrogenesis in mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 1640-1648.	3.8	7
485	A Duffy antigen receptor for chemokines (DARC) polymorphism that determines pro-fibrotic chemokine serum concentrations is not directly associated with severity of hepatitis C infection. Human Immunology, 2011, 72, 273-277.	2.4	8
486	Distinct, alcohol-modulated effects of PNPLA3 genotype on progression of chronic hepatitis C. Journal of Hepatology, 2011, 55, 732-733.	3.7	32

#	Article	IF	Citations
487	Increased liver stiffness denotes hepatic dysfunction and mortality risk in critically ill non-cirrhotic patients at a medical ICU. Critical Care, 2011, 15, R266.	5.8	64
488	Why high suPAR is not super - diagnostic, prognostic and potential pathogenic properties of a novel biomarker in the ICU. Critical Care, 2011 , 15 , 1020 .	5.8	23
489	Acute Liver Failure. Deutsches Ärzteblatt International, 2011, 108, 714-20.	0.9	78
490	Interleukin-8 Is Activated in Patients with Chronic Liver Diseases and Associated with Hepatic Macrophage Accumulation in Human Liver Fibrosis. PLoS ONE, 2011, 6, e21381.	2.5	222
491	CXCL5 plasma levels decrease in patients with chronic liver disease. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 523-529.	2.8	24
492	Serum chemokine receptor CXCR3 ligands are associated with progression, organ dysfunction and complications of chronic liver diseases. Liver International, 2011, 31, 840-849.	3.9	54
493	From proteomic multimarker profiling to interesting proteins: thymosinâ€Î²⟨sub⟩4⟨/sub⟩ and kininogenâ€Î as new potential biomarkers for inflammatory hepatic lesions. Journal of Cellular and Molecular Medicine, 2011, 15, 2176-2188.	3.6	19
494	Serum adiponectin upon admission to the intensive care unit may predict mortality in critically ill patients. Journal of Critical Care, 2011, 26, 166-174.	2.2	78
495	Y-box protein-1/p18 fragment identifies malignancies in patients with chronic liver disease. BMC Cancer, 2011, 11, 185.	2.6	22
496	Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology, 2011, 53, 209-218.	7.3	696
497	Controlling autophagy: A new concept for clearing liver disease. Hepatology, 2011, 53, 356-358.	7.3	12
498	Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection. Hepatology, 2011, 53, 596-603.	7.3	70
499	Infiltrating monocytes versus resident kupffer cells: Do alternatively activated macrophages need to be targeted alternatively?. Hepatology, 2011, 54, 2269-2271.	7.3	13
500	Modification of Chemokine Pathways and Immune Cell Infiltration as a Novel Therapeutic Approach in Liver Inflammation and Fibrosis. Inflammation and Allergy: Drug Targets, 2011, 10, 509-536.	1.8	101
501	Assessment of Inflammatory and Fibrotic Stenoses in Patients with Crohn's Disease Using Contrast-Enhanced Ultrasound and Computerized Algorithm: A Pilot Study. Digestion, 2011, 83, 263-268.	2.3	33
502	Role of IL-17 and Th17 Cells in Liver Diseases. Clinical and Developmental Immunology, 2011, 2011, 1-12.	3.3	202
503	Comparison of gene expression profiles between human and mouse monocyte subsets. Blood, 2010, 115, e10-e19.	1.4	609
504	TAK1 Suppresses a NEMO-Dependent but NF-κB-Independent Pathway to Liver Cancer. Cancer Cell, 2010, 17, 481-496.	16.8	207

#	Article	IF	Citations
505	Dendritic cells in liver fibrosis: conductor of the inflammatory orchestra?. Hepatology, 2010, 51, 1070-1072.	7.3	12
506	The fractalkine receptor CX3CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes. Hepatology, 2010, 52, 1769-1782.	7.3	203
507	Age-dependent alterations of monocyte subsets and monocyte-related chemokine pathways in healthy adults. BMC Immunology, 2010, 11, 30.	2.2	318
508	Functional Contribution of Elevated Circulating and Hepatic Non-Classical CD14+CD16+ Monocytes to Inflammation and Human Liver Fibrosis. PLoS ONE, 2010, 5, e11049.	2.5	279
509	Differential Impact of Immune Escape Mutations G145R and P120T on the Replication of Lamivudine-Resistant Hepatitis B Virus e Antigen-Positive and -Negative Strains. Journal of Virology, 2010, 84, 1026-1033.	3.4	40
510	Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. Journal of Experimental Medicine, 2010, 207, 1453-1464.	8.5	295
511	Tip-DC Development during Parasitic Infection Is Regulated by IL-10 and Requires CCL2/CCR2, IFN- \hat{l}^3 and MyD88 Signaling. PLoS Pathogens, 2010, 6, e1001045.	4.7	124
512	Relevance of Serum Leptin and Leptin-Receptor Concentrations in Critically Ill Patients. Mediators of Inflammation, 2010, 2010, 1-9.	3.0	56
513	Regulatory T Cells and Immune Tolerance to Coagulation Factor IX in the Context of Intramuscular AAV1 Gene Transfer. Molecular Therapy, 2010, 18, 361-369.	8.2	4
514	Chemokines in Liver Inflammation and Fibrosis. Seminars in Liver Disease, 2010, 30, 215-225.	3.6	148
515	Regulation and prognostic relevance of serum ghrelin concentrations in critical illness and sepsis. Critical Care, 2010, 14, R94.	5.8	56
516	Circulating retinol binding protein 4 in critically ill patients before specific treatment: prognostic impact and correlation with organ function, metabolism and inflammation. Critical Care, 2010, 14, R179.	5.8	46
517	Analysis of antigen-presenting functionality of cultured rat hepatic stellate cells and transdifferentiated myofibroblasts. Biochemical and Biophysical Research Communications, 2010, 396, 342-347.	2.1	44
518	Monocytic suppressive cells mediate cardiovascular transplantation tolerance in mice. Journal of Clinical Investigation, 2010, 120, 2486-2496.	8.2	190
519	Mouse models of hepatocarcinogenesis: What can we learn for the prevention of human hepatocellular carcinoma?. Oncotarget, 2010, 1, 373-378.	1.8	43
520	Mouse models of hepatocarcinogenesis: what can we learn for the prevention of human hepatocellular carcinoma?. Oncotarget, 2010, 1, 373-8.	1.8	28
521	Which is the IDEAL peginterferon for Hepatitis C: a meta-analysis of both pegylated interferons in the treatment of HCV-infected patients. Hepatitis Monthly, 2010, 10, 229-30.	0.2	0
522	Monocytes and Macrophages as Cellular Targets in Liver Fibrosis. Inflammation and Allergy: Drug Targets, 2009, 8, 307-318.	1.8	150

#	Article	IF	CITATIONS
523	The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-negative hepatitis B virus strains. Hepatology, 2009, 49, 1158-1165.	7.3	118
524	Hepatic recruitment of the inflammatory Gr1 ⁺ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology, 2009, 50, 261-274.	7.3	664
525	Inflammatory Pathways in Liver Homeostasis and Liver Injury. Clinical Reviews in Allergy and Immunology, 2009, 36, 4-12.	6.5	348
526	Hepatitis E vaccine: current status and future prospects. Future Virology, 2009, 4, 143-154.	1.8	4
527	Serum resistin levels in critically ill patients are associated with inflammation, organ dysfunction and metabolism and may predict survival of non-septic patients. Critical Care, 2009, 13, R95.	5.8	155
528	Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome. Journal of Hepatology, 2009, 51, 647-654.	3.7	23
529	Antifibrotic Effects of CXCL9 and Its Receptor CXCR3 in Livers of Mice and Humans. Gastroenterology, 2009, 137, 309-319.e3.	1.3	149
530	Differential regulation of chemokine CCL5 expression in monocytes/macrophages and renal cells by Y-box protein-1. Kidney International, 2009, 75, 185-196.	5.2	45
531	Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient. Aids, 2009, 23, 268-272.	2.2	22
532	Hepatocyte-specific inhibitor-of-kappaB-kinase deletion triggers the innate immune response and promotes earlier cell proliferation during liver regeneration. Hepatology, 2008, 47, 2036-2050.	7.3	50
533	Hepatitis B goes globe: Telbivudine as a new treatment option. Hepatology, 2008, 47, 1786-1787.	7.3	2
534	Liver function critically determines serum retinol-binding protein 4 (RBP4) levels in patients with chronic liver disease and cirrhosis. Hepatology, 2008, 48, 1724-1725.	7.3	19
535	High C5a levels are associated with increased mortality in sepsis patients — No enhancing effect by actin-free Gc-globulin. Clinical Biochemistry, 2008, 41, 974-980.	1.9	29
536	The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection. Journal of Hepatology, 2008, 48, 208-215.	3.7	66
537	Chemokine-directed immune cell infiltration in acute and chronic liver disease. Expert Review of Gastroenterology and Hepatology, 2008, 2, 233-242.	3.0	118
538	Blood Monocyte Subsets Differentially Give Rise to CD103+ and CD103â ⁻ Pulmonary Dendritic Cell Populations. Journal of Immunology, 2008, 180, 3019-3027.	0.8	208
539	Gp130 Signaling Promotes Development of Acute Experimental Colitis by Facilitating Early Neutrophil/Macrophage Recruitment and Activation. Journal of Immunology, 2008, 181, 3586-3594.	0.8	37
540	CCR2 Mediates Homeostatic and Inflammatory Release of Gr1high Monocytes from the Bone Marrow, but Is Dispensable for Bladder Infiltration in Bacterial Urinary Tract Infection. Journal of Immunology, 2008, 181, 5579-5586.	0.8	86

#	Article	IF	CITATIONS
541	Symptomatic Hepatitis B Virus (HBV) Reactivation despite Reduced Viral Fitness Is Associated with HBV Test and Immune Escape Mutations in an HIVâ€Coinfected Patient. Journal of Infectious Diseases, 2008, 198, 1620-1624.	4.0	28
542	Protective Role of CXC Receptor 4/CXC Ligand 12 Unveils the Importance of Neutrophils in Atherosclerosis. Circulation Research, 2008, 102, 209-217.	4.5	363
543	The role of chemokines and their receptors in dendritic cell biology. Frontiers in Bioscience - Landmark, 2008, 13, 2238.	3.0	45
544	Insulin Resistance in Liver Cirrhosis Is Not Associated With Circulating Retinol-Binding Protein 4. Diabetes Care, 2007, 30, 1168-1172.	8.6	61
545	A simple clinical score predicts high risk for upper gastrointestinal hemorrhages from varices in patients with chronic liver disease. Scandinavian Journal of Gastroenterology, 2007, 42, 374-382.	1.5	34
546	Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. Journal of Clinical Investigation, 2007, 117, 185-194.	8.2	1,117
547	Acute hepatitis B virus infection by genotype F despite successful vaccination in an immune-competent German patient. Journal of Clinical Virology, 2007, 38, 353-357.	3.1	55
548	Causes of death in hepatitis B and/or C virus infected–people—lessons for clinical practice. Hepatology, 2007, 45, 1076-1077.	7.3	0
549	Efficient recombinant hepatitis E virus vaccine: Mission accomplished?. Hepatology, 2007, 46, 941-943.	7. 3	10
550	Elevated apoptosis-associated cytokeratin 18 fragments (CK18Asp386) in serum of patients with chronic liver diseases indicate hepatic and biliary inflammation. Clinical Biochemistry, 2007, 40, 651-655.	1.9	51
551	Up-regulated eotaxin plasma levels in chronic liver disease patients indicate hepatic inflammation, advanced fibrosis and adverse clinical course. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 1256-1264.	2.8	29
552	Bone Morphogenetic Protein 7 is Elevated in Patients with Chronic Liver Disease and Exerts Fibrogenic Effects on Human Hepatic Stellate Cells. Digestive Diseases and Sciences, 2007, 52, 3404-3415.	2.3	60
553	Migratory fate and differentiation of blood monocyte subsets. Immunobiology, 2006, 211, 609-618.	1.9	452
554	Clinical and prognostic role of plasma coagulation factor XIII activity for bleeding disorders and 6-year survival in patients with chronic liver disease. Liver International, 2006, 26, 173-181.	3.9	33
555	Langerhans cells arise from monocytes in vivo. Nature Immunology, 2006, 7, 265-273.	14.5	627
556	Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nature Immunology, 2006, 7, 652-662.	14.5	589
557	Elevation of NÎμ-(carboxymethyl)lysine-modified advanced glycation end products in chronic liver disease is an indicator of liver cirrhosis. Clinical Biochemistry, 2006, 39, 39-45.	1.9	71
558	Serum hepatitis B virus DNA level as a risk predictor for liver disease complications. Nature Reviews Gastroenterology & Hepatology, 2006, 3, 426-427.	1.7	2

#	Article	IF	CITATIONS
559	Modulation of Dendritic Cell Trafficking to and from the Airways. Journal of Immunology, 2006, 176, 3578-3584.	0.8	234
560	Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3781-3786.	7.1	313
561	Immature monocytes acquire antigens from other cells in the bone marrow and present them to T cells after maturing in the periphery. Journal of Experimental Medicine, 2006, 203, 583-597.	8.5	235
562	A Novel Model of Demyelinating Encephalomyelitis Induced by Monocytes and Dendritic Cells. Journal of Immunology, 2006, 177, 6871-6879.	0.8	38
563	A reply to Siciliano et al Scandinavian Journal of Gastroenterology, 2005, 40, 124-124.	1.5	0
564	High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. Journal of Hepatology, 2005, 42, 666-673.	3.7	111
565	Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antiviral Therapy, 2005, 10, 727-34.	1.0	88
566	Selection of Hepatitis B Virus Polymerase Mutations in HIV-Coinfected Patients Treated with Tenofovir. Antiviral Therapy, 2005, 10, 727-734.	1.0	249
567	Influence of Mutations in the Hepatitis B Virus Genome on Virus Replication and Drug Resistance - Implications for Novel Antiviral Strategies. Current Medicinal Chemistry, 2004, 11, 2667-2677.	2.4	34
568	Expression of Inducible Bcl-XS in Myeloid Leukemia: Compensatory Upregulation of Bcl-XL and Bcl-2 Prevents Apoptosis and Chemosensitization. Cancer Biology and Therapy, 2004, 3, 340-347.	3.4	15
569	Basal Core Promoter and Precore Mutations in the Hepatitis B Virus Genome Enhance Replication Efficacy of Lamivudine-Resistant Mutants. Journal of Virology, 2004, 78, 8524-8535.	3.4	116
570	C/EBP ? isoforms LIP and LAP modulate progression of the cell cycle in the regenerating mouse liver. Hepatology, 2004, 40, 356-365.	7.3	61
571	Role of CCR8 and Other Chemokine Pathways in the Migration of Monocyte-derived Dendritic Cells to Lymph Nodes. Journal of Experimental Medicine, 2004, 200, 1231-1241.	8.5	266
572	Regulation of plasma erythropoietin in chronic liver disease. World Journal of Gastroenterology, 2004, 10, 2922.	3.3	5
573	p18(INK4c) collaborates with other CDK-inhibitory proteins in the regenerating liver. Hepatology, 2003, 37, 833-841.	7.3	29
574	Interleukin $6/gp130$ -dependent pathways are protective during chronic liver diseases. Hepatology, 2003, 38, 218-229.	7.3	144
575	Relevance of hepatitis B core gene deletions in patients after kidney transplantation. Gastroenterology, 2003, 124, 1809-1820.	1.3	27
576	Ghrelin in chronic liver disease. Journal of Hepatology, 2003, 38, 447-454.	3.7	97

#	Article	IF	CITATION
577	Plasma P-selectin levels are elevated in patients with chronic liver disease. Blood Coagulation and Fibrinolysis, 2003, 14, 319-325.	1.0	18
578	Thrombopoietin serum levels are elevated in patients with hepatitis B/C infection compared to other causes of chronic liver disease. Liver, 2002, 22, 114-120.	0.1	25
579	Quantification of hepatic thrombopoietin mRNA transcripts in patients with chronic liver diseases shows maintained gene expression in different etiologies of liver cirrhosis. Liver, 2002, 22, 205-212.	0.1	14
580	Adipocytokines in Severe Sepsis and Septic Shock., 0,,.		0